Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry.
about
Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cellsThe Origin and Activities of IgA1-Containing Immune Complexes in IgA NephropathyEnzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathyEffect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA NephropathySpecific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces.Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1The genetics and immunobiology of IgA nephropathy.Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individualsElucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing.Longitudinal monitoring of immunoglobulin A glycosylation during pregnancy by simultaneous MALDI-FTICR-MS analysis of N- and O-glycopeptidesThe solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN diseaseIgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.Naturally occurring structural isomers in serum IgA1 o-glycosylation.Pathogenesis of Henoch-Schönlein purpura nephritis.Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes.Immunoglobulin A: A next generation of therapeutic antibodies?Structure and function relationships in IgA.Glycosylation of IgA1 and pathogenesis of IgA nephropathy.Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers.Upstream and downstream processing of recombinant IgA.Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management.Immunoglobulin A nephropathy: a pathophysiology view.IgA EGFR antibodies mediate tumour killing in vivo.Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.Human immunoglobulin glycosylation and the lectin pathway of complement activation.Comparative Glycomics of Immunoglobulin A and G From Saliva and Plasma Reveals Biomarker PotentialIdentification of a new European rabbit IgA with a serine-rich hinge region
P2860
Q24680134-AD511440-B8F3-4EA7-A31D-B88404252B1EQ26752555-51A7B716-B61F-4279-BFE3-09F5BF59EAD7Q28539595-9DAC44D6-727C-4B50-86B5-630F3BD86137Q28554822-80440242-0932-49C3-A343-BB0659EE4353Q33347255-E5CCEB2B-9A92-4800-9491-EF3B4F664D23Q33812834-40D5C39D-CEDC-4DB9-BDF9-BA78579141DFQ33872517-AEA7B8E0-A1EE-4D8E-9172-0B69EAC4CE9EQ34468379-31826C33-26C9-4ABA-9F95-37428E29C78AQ34869928-3F9936E8-AF70-45C9-B902-38E8FCE94821Q36052433-E3EFE293-30E0-4C65-8910-1AE4D83AC328Q36406807-9342A2FD-CF20-4A4A-BA98-C8F95AA9DCFEQ36456627-394C8463-03E8-4341-BAE7-0FDC393842FFQ37352215-8BFEC01B-5236-42BD-87A4-DDBE8C80780BQ37424655-AE1ED78F-2C63-446F-9F29-94F3590249C1Q37578868-8F27A5DE-E746-49F5-B63A-7F953CE198C8Q37596411-E78B769F-E74B-41B4-A37C-CD3670F07CA8Q37892323-37701B6F-44B1-4C94-B44B-F8CEE1BC3585Q37936765-7A6CCE37-86CF-4123-836A-79A1C9C5E3FBQ37995525-639DDE7C-5E30-4030-8960-4E1F150D1AB9Q38121846-51E3C110-E413-4D95-A5E4-9713EA38CC0DQ38254478-016F64F7-CF8D-4238-B4E8-93049FE178DCQ38306917-3F91DE12-72D4-431A-8E5A-FB849AD07791Q38879517-74CB2B71-39AB-4051-9C9B-E628FAB53470Q39114924-A770C8EB-1E51-4653-9847-368B4B1BE730Q41844193-D8CAFF54-26E5-497C-8498-010473BE3991Q53606289-048232E1-3B3D-4292-8809-85376C1328CCQ58572572-4C1B6602-6FAE-4320-A9BB-B32A3697044CQ58796201-BE027A26-046C-4950-8AC8-A52AA6B2127D
P2860
Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Human serum IgA1 is substitute ...... e-of-flight mass spectrometry.
@ast
Human serum IgA1 is substitute ...... e-of-flight mass spectrometry.
@en
type
label
Human serum IgA1 is substitute ...... e-of-flight mass spectrometry.
@ast
Human serum IgA1 is substitute ...... e-of-flight mass spectrometry.
@en
prefLabel
Human serum IgA1 is substitute ...... e-of-flight mass spectrometry.
@ast
Human serum IgA1 is substitute ...... e-of-flight mass spectrometry.
@en
P2093
P1476
Human serum IgA1 is substitute ...... me-of-flight mass spectrometry
@en
P2093
Alice C Smith
Bruce M Hendry
Edward Tarelli
Shideh Pouria
P304
P356
10.1016/J.CARRES.2004.07.011
P577
2004-09-01T00:00:00Z